# Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)

> **NCT06903130** · — · NOT_YET_RECRUITING · sponsor: **National and Kapodistrian University of Athens** · enrollment: 40 (estimated)

## Conditions studied

- NMOSD

## Interventions

- **DIAGNOSTIC_TEST:** Blood samples for sNfL and sGFAP levels

## Key facts

- **NCT ID:** NCT06903130
- **Lead sponsor:** National and Kapodistrian University of Athens
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06903130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06903130, "Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06903130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*